Also, if you look at the economic activity, since COVID we have been at breakneck speed. Even on that count, we needed a breather and this period has given, last say two quarters have given us a period where we are kind of taking a breather on even economic activity, that also sets the platform very nicely for future growth.
Biocon buys back an investor stake in biologics unit, posts Rs 25 crore net profit in Q3FY25
Biocon’s board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected
January 30, 2025